Alexza Pharmaceuticals, Inc.' Corporate Presentation To Be Webcast From Two Upcoming March Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 20, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today its corporate presentation will be webcast live from two upcoming investor conferences. The webcast of each presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at www.alexza.com. The conferences and presentation times are:

• Cowen & Company 34^th Annual Health Care Conference in Boston, MA on Monday, March 3, 2014 at 4:50 pm ET, direct link to the webcast at wsw.com/webcast/cowen16/ALXA
• 26^th Annual ROTH Conference in Dana Point, CA on Monday, March 10, 2014 at 11:30 am ET, direct link to the webcast at wsw.com/webcast/roth28/ALXA

A replay of each webcast will be available approximately 24 hours following the presentation and each replay will be available for 30 days on the Investor Relations section of Alexza's website.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products are based on the Staccato^® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE^® (Staccato loxapine) is Alexza's first commercial product, which was approved by the U.S. Food and Drug Administration in December 2012 and by the European Commission in February 2013. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement
The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and our partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Logo: http://photos.prnewswire.com/prnh/20140121/SF49110LOGO

SOURCE Alexza Pharmaceuticals, Inc.